空心针活检在鉴别侵袭性良性骨肿瘤与恶性溶骨性骨肿瘤中是否可靠?
该回顾性研究纳入1990至2016年因动脉瘤样骨囊肿或毛细血管扩张型骨肉瘤行空心针活检并接受 definitive 手术切除的病例,评估空心针活检的有效性、准确性及并发症。81%的活检有效,93%的有效活检准确;恶性诊断敏感度89%、特异度100%、阳性预测值1.00、阴性预测值0.82,无并发症。院内与院外活检的有效性和准确性无显著差异。
要点
- 81%(59/73)的空心针活检有效,93%(55/59)的有效活检诊断准确。
- 恶性诊断敏感度89%(8/9)、特异度100%(51/51)、阳性预测值1.00、阴性预测值0.82。
- 空心针活检与 definitive 手术间无并发症;院内与院外活检有效性和准确性无显著差异。
核心结论
- 数据提示空心针活检可作为动脉瘤样骨囊肿和毛细血管扩张型骨肉瘤的初始诊断检查。
- 院外空心针活检组织可可靠判读,无需重复活检。
- 若被其他机构证实,空心针活检可考虑作为侵袭性溶骨性骨病变诊断的合理方法。
研究设计与样本
- 回顾性研究,检索1990至2016年肌肉骨骼肿瘤委员会病理数据库,关键词为「动脉瘤样骨囊肿」或「毛细血管扩张型骨肉瘤」。
- 仅纳入接受空心针活检并进一步行 definitive 手术切除且获最终病理的患者。
- 排除院外空心针活检后,空心针活检在患者就诊于肌肉骨骼肿瘤委员会后因影像学或病史不典型提示恶性而进行。
- 院外空心针活检组织由本院病理医师复审;若组织足够诊断则行 definitive 手术,否则行切开活检。
- 记录空心针活检与 definitive 开放手术之间(平均1.6个月)的并发症,包括出血、感染、神经损伤、再入院或骨折。
主要发现
- 81%(59/73)的空心针活检有效。
- 93%(55/59)的空心针活检归类为准确。
- 诊断性空心针活检的敏感度和特异度分别为89%(8/9)和100%(51/51)。
- 阳性预测值为1.00,阴性预测值为0.82。
- 无并发症发生。
关键数值与推荐
- 空心针活检「有效」定义为获得足以在不额外行切开活检的情况下进行适当 definitive 手术的病理。
- 空心针活检「准确」定义为有效且病理诊断与后续 definitive 手术病理一致。
- 恶性诊断的敏感度89%(8/9)、特异度100%(51/51)、阳性预测值1.00、阴性预测值0.82。
临床怎么用
- 作者认为空心针活检可作为动脉瘤样骨囊肿和毛细血管扩张型骨肉瘤的初始诊断检查。
- 作者认为院外空心针活检组织可可靠判读,无需重复活检。
- 作者建议若被其他机构证实,空心针活检可考虑作为侵袭性溶骨性骨病变诊断的合理方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although there is widespread acceptance of core needle biopsy (CNB) for diagnosing solid tumors, there is reluctance by some clinicians to use CNB for aneurysmal bone cysts (ABCs) as a result of concerns of safety (bleeding, nerve injury, fracture, readmission, or infection) and reliability, particularly to rule out malignant diagnoses like telangiectatic osteosarcoma. This is especially true when CNB tissue is sent from an outside hospital, where the technique used to obtain the tissue may be spurious. QUESTIONS/PURPOSES: (1) Is CNB effective (provided adequate information to indicate appropriate surgical treatment without further open biopsy) as an initial diagnostic test for ABC? (2) Is CNB accurate (pathology consistent with the subsequent definitive surgical pathologic diagnosis) in differentiating between benign lesions such as primary or secondary ABCs and malignant radiolucent lesions such as telangiectatic osteosarcoma? (3) What are the complications of CNB? (4) Is there any difference in the effectiveness or accuracy of CNB performed at outside institutions when compared with a referral center? METHODS: A retrospective study of our musculoskeletal tumor board pathology database (1990-2016) was performed using search criteria "aneurysmal bone cyst" or "telangiectatic osteosarcoma." Only patients undergoing a CNB who proceeded to definitive surgical resection with final pathology were included. Excluding outside CNBs, CNB was performed after presentation at a musculoskeletal tumor board as a result of atypical features on imaging or history concerning for malignancy. Outside CNB tissue was reviewed by our pathologists. If there was sufficient tissue for diagnosis, the patient proceeded to definitive surgery. If not, the patient underwent open biopsy. CNB diagnosis, open biopsy results, and open surgical resection pathology were reviewed. Complications, including bleeding, infection, nerve injury, readmission, or fracture, between the CNB and definitive open surgical procedure (mean 1.6 months) were documented. CNBs were considered "effective" if they yielded pathology considered sufficient to proceed with appropriate definitive surgery without additional open biopsy. CNBs were considered "accurate" if they were effective and yielded a pathologic diagnosis that matched the subsequent definitive surgical pathology. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of obtaining a malignant diagnosis using CNB were also calculated. RESULTS: A total of 81% (59 of 73) of CNBs were effective. Ninety-three percent (55 of 59) of CNBs were classified as accurate. Diagnostic CNBs had a sensitivity and specificity of 89% (eight of nine) and 100% (51 of 51), respectively. The PPV was 1.00 and the NPV was 0.82. There were no complications. With the numbers available, there was no difference in efficacy (90% [37 of 41 versus 14 of 15]; odds ratio, 0.97 [95% confidence interval {CI}, 0.41-2.27], p = 0.94) or accuracy (92% [34 of 37 versus 13 of 14]; odds ratio, 0.87 [95% CI, 0.08-9.16], p = 0.91) between CNBs performed in house and those referred from outside. CONCLUSIONS: These data suggest that CNBs are useful as an initial diagnostic test for ABC and telangiectatic osteosarcoma. Tissue from outside CNBs can be read reliably without repeat biopsy. If confirmed by other institutions, CNB may be considered a reasonable approach to the diagnosis of aggressive, radiolucent lesions of bone. LEVEL OF EVIDENCE: Level III, diagnostic study.
引用
- Hegde V, Burke ZDC, Park HY, et al. Is Core Needle Biopsy Reliable in Differentiating Between Aggressive Benign and Malignant Radiolucent Bone Tumors? Clin Orthop Relat Res. 2018. PMID: 29529643. doi:10.1007/s11999.0000000000000062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。